Novo says Wegovy injection lowers BMI and obesity rates in children in trial
Novo Nordisk reported that its Wegovy injection significantly reduced BMI in children aged 6 to 12 with obesity in a late-stage trial. The drug lowered BMI by 19.7 percentage points more than a placebo at 68 weeks. Novo aims to address a treatment gap for childhood obesity, with 85% of trial participants starting with moderate to severe obesity. Wegovy is already approved for children aged 12 and older.
How this was made

The 30-second read
Why it matters
The data could trigger FDA pediatric trial extensions and broaden the drug's addressable market, influencing Novo Nordisk's long‑term growth outlook.
Market read
First disclosure of pediatric efficacy for a blockbuster obesity drug, likely to affect Novo Nordisk valuation and sector sentiment.
What to watch
Potential reimbursement challenges and competition from emerging obesity drugs could limit upside
Background
Wegovy is already approved for adults and adolescents 12+, but no therapy exists for children under 12. The trial enrolled 167 participants with moderate to severe obesity.
Ticker impact
Novo Nordisk released full results of a late‑stage Wegovy trial showing significant BMI reduction in children under 12, a first‑time indication for the drug.
likely upward pressure as investors price in expanded pediatric indication
The trial is the first public disclosure of efficacy in a new age group, a material catalyst for future sales and regulatory filings.
Market effects
strengthens the obesity‑treatment segment and may boost biotech peers developing similar GLP‑1 therapies
U.S. and European markets could see modest gains in pharma stocks
global relevance as obesity is a worldwide health issue and Wegovy is marketed internationally
Counterpoint
Regulatory approval for pediatric use may face additional safety scrutiny, delaying commercialization
Key entities
- companyNovo Nordisk
Pharmaceutical company developing Wegovy
- productWegovy
GLP‑1 obesity treatment

